BIOSTEM TECHNOLOGIES INC |
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| 14/05 | Earnings Flash (BSEM) BIOSTEM TECHNOLOGIES Reports Q1 Revenue $41.9M | MT |
| 2023 | NovaBay to Commercialize BioStem's Amniotic Tissue Allograft | MT |
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
Andrew van Vurst
FOU | Founder | - | 07/06/07 |
| Chief Executive Officer | - | 07/06/07 | |
| Director of Finance/CFO | - | 01/21/01 | |
Wendy Weston
CTO | Chief Tech/Sci/R&D Officer | 48 | 01/20/01 |
Joseph Babiak
CIO | Chief Investment Officer | - | - |
Dave Woynarowski
CTO | Chief Tech/Sci/R&D Officer | - | 01/16/01 |
Ken Warrington
BRD | Director/Board Member | - | 29/19/29 |
| Sales & Marketing | - | - | |
Neal Bhattcharya
SAM | Sales & Marketing | - | 01/23/01 |
Larry Jones
PRN | Corporate Officer/Principal | - | 18/18/18 |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
Thomas Dugan
CHM | Chairman | 66 | 13/12 |
Patrick Daly
BRD | Director/Board Member | - | 19/12 |
| Chief Executive Officer | - | 07/06/07 | |
Andrew van Vurst
FOU | Founder | - | 07/06/07 |
Ken Warrington
BRD | Director/Board Member | - | 29/19/29 |
| - | - | ||
Brandon Poe
BRD | Director/Board Member | - | 07/22/07 |
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 0 | 5 | 0 | 0 | 99.00 % |
| Stock B | 1 | 16,214,390 | 16,052,246 ( 99.00 %) | 0 | |
| Stock C | 0 | 300 | 0 | 0 |
Company contact information
BioStem Technologies, Inc.
2836 Center Port Circle
33064, Pompano Beach
+954 380 8342
http://www.biostemtechnologies.com
Sector
| 1st Jan change | Capi. | |
|---|---|---|
| +7.48% | 11TCr | |
| +11.19% | 11TCr | |
| +0.41% | 2.23TCr | |
| -11.81% | 2.22TCr | |
| -5.99% | 1.94TCr | |
| -37.36% | 1.79TCr | |
| -5.91% | 1.72TCr | |
| +7.03% | 1.43TCr | |
| +35.74% | 1.25TCr |
- Stock Market
- Equities
- Stock
- Company Biostem Technologies Inc